anti-CD3/anti-IGFR-1 bispecific T-cell engager (Micromet)

N/A

Report date: 2026/03/19 16:58:23

Base Information

Drug Nameanti-CD3/anti-IGFR-1 bispecific T-cell engager (Micromet)

Drug Alias NameIGFR-1-targeting BiTE antibody (Micromet)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsInsulin-like growth factor I receptor modulators

TargetsInsulin-like growth factor I receptorT cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Rockville Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmgen Rockville Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A